Dengue costs Indonesia nearly Rp9tn in 2024, study finds
A study from Gadjah Mada University reveals that dengue fever cost Indonesia nearly Rp9 trillion in 2024, resulting in over 2 million hospitalizations. The findings highlight the ongoing financial burden on both the healthcare system and individual families.
Why it matters
The economic and health impact of dengue remains a critical public health challenge, necessitating more robust prevention strategies and policy interventions.
Jakarta, IO – Dengue is no longer just a seasonal disease in Indonesia. The risk of transmission is present throughout the year, demanding prevention efforts to stay consistent and long-term. Dengue also financially burden the healthcare system, patients, and their families.
A new study by researchers at Gadjah Mada University (UGM) estimates that dengue cost Indonesia nearly Rp9 trillion (US$550.9 million) in 2024, while causing more than 2 million hospitalizations. The findings underscore why dengue remains one of the country’s top public health challenges and highlight the need for a more comprehensive prevention strategy involving multiple stakeholders.
For that, PT Takeda Innovative Medicines, in collaboration with the Jakarta chapter of the Indonesian Pediatric Society (IDAI Jaya), hosted the Jakarta Dengue Forum (JDF). The forum brought together more than 300 healthcare professionals to discuss strategies to strengthen dengue prevention across Indonesia.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in